A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
Study sponsor: Aardvark Therapeutics, Inc. · AARD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-13Actual
Enrollment · participants5Actual
Source updated2025-05-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.